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Background. Cystic Fibrosis patients with 
nonsense-mutation in the CFTR gene generally 
make virtually no CFTR protein and thus often 
have a more severe form of CF. Recently, 
Ataluren (formerly PTC124) was suggested to 
induce the read-through of premature 
termination codons (PTCs) mainly the UGA 
codon. However, despite promising results there 
is not a general consensus of Ataluren efficacy 
and mechanism of action. 
 
Hypothesis and objectives. The design of new 
small molecules (PTC124 related) together with 
the understanding of their mechanism of action 
could lead to new pharmacologic approaches for 
the cure of CF caused by nonsense mutations in 
the CFTR gene. This project was aimed to 
evaluate the activity of some PTC124 analogues 
identified by a virtual screening, by different 
orthogonal assays with vectors containing PTCs in 
reporter genes and in CF bronchial epithelial cells. 
 
Methods. Design and synthesis of the new PTC’s 
read-through promoters was based on a virtual 
screening approach (1) and starting from the 
results obtained in our precedent study (2). We 
used the FLuc assay, the green fluorescent 
protein assay (GFP) and the IB3 cell line to test 
the new identified products (3-4). In order to 
understand their mechanism of action 
computational studies were done to model the 
interaction between the bioactive synthesized 
compounds and the cellular target. 
 
Results. We synthesized 18 analogues of Ataluren 
(PTC124) and tested them in three different 
biological models. Ten of these new compounds 
showed high read-through capacity (unpublished 
results). 
 
Spin off for research & clinical purposes. 
Identification of molecules displaying 
readthrough activity higher than Ataluren 
(PTC124). Understanding the mechanism of 
action of readthrough promoting molecules. 
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